Pharming

Sole Financial Adviser

Van Lanschot Kempen is acting as Sole Financial Adviser to Pharming in the proposed SEK 725 million recommended cash offer to shareholders of Abliva, providing a repeat client with broad support based on extensive experience in the Nordic life sciences ecosystem

Transaction highlights

On 15 December 2024, Pharming (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announced a public cash offer to the shareholders of Abliva (STO: ABLI)
Abliva shareholders are envisaged to receive SEK 0.45 for each outstanding share in Abliva, bringing the total consideration for Abliva to approximately SEK 725 million
Undertakings to accept the offer have been obtained from the three largest shareholders, accounting for c. 50% of Abliva's outstanding shares
With the proposed acquisition of Abliva, Pharming aims to accelerate the development of KL1333, a promising treatment for mitochondrial diseases, enhancing their pipeline of transformative rare disease medicines. This intended strategic acquisition underscores Pharming’s commitment to bring innovative solutions to patients and its vision to become a leading global rare disease company of choice for patients and partners
Van Lanschot Kempen is acting as Sole Financial Adviser to Pharming providing a repeat client with broad support based on extensive experience in the Nordic life sciences ecosystem, one of Van Lanschot Kempen’s key focus markets

Company description

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercialising and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia Pacific.

Background Van Lanschot Kempen Life Sciences & Healthcare

Most recently, Van Lanschot Kempen served as the Financial Advisor to NewAmsterdam Pharma in relation to its USD 479 million public offering, Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank, Lead Manager in the USD 1.0 billion and USD 460 million Capital Increases by Zealand Pharma and Merus respectively, and Sole Financial Adviser to Pharming Group in the refinancing of its convertible bonds
Van Lanschot Kempen is the most active buyside adviser in public to private transactions in the Netherlands since 2019 and has advised several Dutch acquirors in international public offers
This transaction follows successful transactions including Vastned Retail’s proposed €1.3 billion reverse merger with Vastned Belgium (pending), HAL Investment’s €4.3 billion public offer for Royal Boskalis Wesminster, CTP’s €1.2 billion public offer for Deutsche Industrie REIT, Infestos’ €218 million public offer for Neways Electronics, Gilde Equity Management’s €80 million public offer for DPA Professionals, and Reggeborgh’s €1.8 billion public offer for VolkerWessels

Contact

Jan De Kerpel

Mail Jan De Kerpel

Hendrik van Donkersgoed

Mail Hendrik van Donkersgoed